Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Michael Camilleri, MD GLP-1 receptor agonists are revolutionizing treatment for diabetes and obesity, but their impact on the gastrointestinal tract demands careful clinical attention. Dr. Peter Buch is joined by Dr. Michael Camilleri, Professor of Medicine at the Mayo Foundation for Medical Education and Research in Rochester, Minnesota, to discuss key findings on gastrointestinal side effects, procedural risks, and the impacts of GLP-1 receptor ago...
Jun 27, 20250
Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Ashwani K. Singal MD, MS, FACG, FAASLD, AGAF Sarcopenia and poor nutrition are often silent threats in chronic liver disease, yet they drastically impact outcomes. Joining Dr. Peter Buch to discuss strategies for recognizing and addressing malnutrition early to improve long-term liver health is Dr. Ashwani Singal. Dr. Singal is a Professor of Medicine at the University of Louisville School of Medicine.
Jun 24, 20250
Host: Peter Buch, MD, FACG, AGAF, FACP Guest: David Fudman, MD As the advanced treatment landscape for inflammatory bowel disease continues to expand, selecting the right therapies has become more complex, with efficacy, safety, patient preferences, disease phenotypes, and more as factors to consider. Learn how to effectively navigate these therapeutic options for ulcerative colitis and Crohn’s disease with Dr. Peter Buch and Dr. David Fudman, Assistant Professor and Director of Inflammatory Bow...
Jun 18, 20250
Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Stefan Holubar, MD, MS When are ostomies necessary in patients with inflammatory bowel disease? Join Dr. Peter Buch and Dr. Stefan Holubar, Director of Research at the IBD Surgery Section at the Cleveland Clinic, as they explore key surgical considerations for both ulcerative colitis and Crohn’s disease, including when to consider temporary versus permanent ileostomies, how to manage complications like anastomotic leaks, and what factors influence th...
Jun 10, 20250
Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Mark Benson, MD Colonic perforations during colonoscopy are rare, but when they occur, taking swift and informed action is critical, particularly to avoid surgical intervention. Joining Dr. Peter Buch to offer his insights on perforation prevention, risk-reduction techniques, and repair strategies is Dr. Mark Benson, an advanced endoscopist and Associate Professor in the Division of Gastroenterology and Hepatology at the University of Wisconsin Schoo...
May 06, 20250
Host: Peter Buch, MD, FACG, AGAF, FACP Guest: J. Andy Tau, MD Topical hemostatic agents play a key role in managing complex bleeding cases, but there’s a lot to keep in mind when selecting which agent to use, like their mechanism and efficacy. Joining Dr. Peter Buch to share top considerations and best practices for using topical hemostatic agents is Dr. J Andy Tau, a board-certified gastroenterologist at Austin Gastroenterology in Texas.
Apr 24, 20250
Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Aasma Shaukat, MD, MPH While fecal immunochemical testing and multitarget stool DNA testing are commonly used to screen for colon cancer, screening rates remain low throughout the United States. With the introduction of blood-based testing modalities, noninvasive colon cancer screening is becoming more accessible than ever. Join host Dr. Peter Buch and Dr. Aasma Shaukat as they discuss the effectiveness of current and emerging methods as well as best...
Mar 26, 20250
Guest: Elisa K. Boden, MD For many patients with Crohn’s disease, surgery is necessary due to complications like strictures and fistulas. Dr. Elisa Boden explores risk factors and potential complications, which she spoke about at the 2025 Crohn’s and Colitis Congress. Dr. Boden is an Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Oregon Health and Science University.
Feb 06, 20250
Guest: Elisa K. Boden, MD For patients with Crohn’s disease who require surgery, a variety of risk factors are involved in postoperative recovery and disease control. Learn how prehabilitation programs and lifestyle modifications can reduce complications during and after surgery with Dr. Elisa Boden, an Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Oregon Health and Science University.
Feb 06, 20250
Guest: Sara Horst, MD, MPH, FACG While inflammatory bowel disease (IBD) does not typically cause significant problems in pregnancy, it’s still essential to discuss potential impacts with patients and monitor them closely. Dr. Sara Horst, a Professor of Medicine at Vanderbilt University Medical Center, joins GI Insights to discuss important considerations for pregnant patients with IBD.
Feb 06, 20250
Guest: Shalini Prasad, PhD Guest: Sriram Muthukumar, PhD Host: Charles Turck, PharmD, BCPS, BCCCP With the constant ups and downs of inflammatory bowel disease (IBD), consistent monitoring can help provide patient-centric care. Dr. Shalini Prasad and Dr. Sriram Muthukumar, co-founders of EnLiSense, join GI Insights to discuss the wearable device they developed to track inflammation markers in IBD patients. Dr. Prasad is the Head of the Department of Bioengineering at the University of Texas at D...
Feb 06, 20250
Host: Peter Buch, MD, FACG, AGAF, FACP Guest: William Chey, MD Recent changes to the American College of Gastroenterology’s guidelines on H. pylori treatment provide recommendations for antibiotic susceptibility and optimal patient management. Dr. Peter Buch sits down with the lead author of these guidelines, Dr. William Chey, to learn more about implications for clinical practice. Dr. Chey is the Chief of the Division of Gastroenterology and Hepatology, the H. Marvin Pollard Professor of Gastro...
Jan 16, 20250
Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Vivek Kaul, MD The American Society for Gastrointestinal Endoscopy (ASGE) recently released a new guideline on when to use endoscopic submucosal dissection (ESD) and endoscopic mucosal resection (EMR) in managing early esophageal and gastric cancers. To learn more about when to use each approach, Dr. Peter Buch sits down with guideline co-author Dr. Vivek Kaul. Dr. Kaul is also the Segal-Watson Professor of Medicine at the University of Rochester Med...
Jan 16, 20250
Host: Peter Buch, MD, FACG, AGAF, FACP Guest: David P. Hudesman, MD With so many therapeutic options for Crohn’s disease and ulcerative colitis, it can be challenging to determine which one best matches your patient’s needs and preferences. Onset of action, risk of infections, disease location, and therapeutic goals are all key factors in the decision-making process. To learn more about these considerations, Dr. Peter Buch sits down with Dr. David Hudesman and explores the current therapeutic la...
Jan 14, 20250
Host: Peter Buch, MD, FACG, AGAF, FACP Guest: David P. Hudesman, MD Patients with inflammatory bowel disease (IBD) can experience a variety of extraintestinal manifestations (EIMs), including joint and eye pain and skin rashes. Dr. Peter Buch sits down with Dr. David Hudesman to discuss the impacts of these EIMs and explore best practices for patient management. Dr. Hudesman is a Professor of Medicine at NYU Grossman School of Medicine and Co-Director of NYU Langone’s Inflammatory Bowel Disease ...
Jan 14, 20250
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sun-Ho Lee, MD, PhD Recent research explored the development, validation, and implications of the GEM integrative risk score (GEM-IRS). To learn how this innovative model helps predict the future risk of Crohn’s Disease in healthy first-degree relatives, Dr. Charles Turck speaks with Dr. Sun-Ho Lee, Assistant Professor and clinician scientist at the Inflammatory Bowel Disease Centre at Mount Sinai Hospital in Toronto, Canada....
Dec 20, 20240
Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Douglas Drossman, MD While neuromodulators are primarily used to treat psychiatric disorders, they can also help normalize symptoms of irritable bowel syndrome by targeting the gut-brain axis. In fact, about half of all patients with IBS have the potential to benefit from neuromodulators. Dr. Douglass Drossman joins Dr. Peter Buch to discuss his research on how various neuromodulators can provide relief for IBS patients. Dr. Drossman is the President...
Nov 12, 20240
Host: Peter Buch, MD, FACG, AGAF, FACP Guest: William Grady, MD While colorectal cancer is the second most common cause of cancer deaths, only a third of people between the ages of 45 and 75 are compliant with screening recommendations. However, cell-free DNA blood-based tests could become a new option for colorectal cancer screening. Dr. Peter Buch sits down with GI expert Dr. William Grady to discuss the efficacy of this new test and where it is in the FDA approval process....
Oct 30, 20240
Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Kyle Staller, MD, MPH The complexities of gastroparesis can make the disease difficult to diagnose and treat. To help us overcome these challenges, Dr. Kyle Staller joins Dr. Peter Buch to share his preferred strategies for managing patients with gastroparesis. Not only is Dr. Staller an Assistant Professor of Medicine at Harvard University, but he’s also the Director of the GI Motility Lab at the Massachusetts General Hospital....
Oct 28, 20240
Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Kyle Staller, MD, MPH Join Dr. Peter Buch as he speaks with Dr. Kyle Staller, Director of the Gastrointestinal Motility Laboratory at Mass General and Assistant Professor of Medicine at Harvard Medical School, about uncovering the cause of a patient’s bloating and determining how to manage it.
Oct 28, 20240
Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Eamonn Quigley, MD Small intestinal bacterial overgrowth (SIBO) is often overdiagnosed due to misconceptions about symptoms and inaccurate tests. Join Dr. Peter Buch and Dr. Eamonn Quigley as they explore considerations for knowing when and how to diagnose and treat SIBO. Dr. Quigley is the Chief of Gastroenterology and Hepatology and the Co-Director of the Lynda K. and David M. Underwood Center for Digestive Disorders at Houston Methodist Hospital....
Oct 18, 20240
Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Brian E. Lacy, MD, PhD About 50 percent of gastrointestinal providers are experiencing some degree of burnout, which can lead to a variety of personal and professional challenges. Joining Dr. Peter Buch to discuss the signs of burnout and what you can do to mitigate them is Dr. Brian Lacy, lead author of the “Burnout in Gastrointestinal Providers” article published in the American Journal of Gastroenterology in 2024....
Oct 18, 20240
Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Edward L. Barnes, MD, MPH Tune in to learn about the newest clinical practice recommendations for pouchitis and inflammatory pouch disorders. Tune in to learn about the newest clinical practice recommendations for pouchitis and inflammatory pouch disorders. Tune in to learn about the newest clinical practice recommendations for pouchitis and inflammatory pouch disorders.
Oct 18, 20240
Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Naga Chalasani, MD, FAASLD It’s recommended that if patients with cirrhosis are using acetaminophen long-term, it should be a limited dosage. But should we be avoiding nonsteroidals in patients with decompensation cirrhosis? To walk through the impacts of analgesics in patients with cirrhosis, join Dr. Peter Buch as he speaks with Dr. Naga Chalasani, David W. Crabb Professor of Gastroenterology and Hepatology at Indiana University School of Medicine....
Sep 03, 20240
Guest: Bryson Katona, MD, PhD At the 2024 Digestive Disease Week Annual Meeting, Dr. Bryson Katona presented a session, titled “High-Risk Colon Cancer: The ABCs of Genetic Testing.” And now, Dr. Katona is here with Dr. Jody Takemoto to share key insights from his session on genetic testing for patients with high-risk colon cancer. Dr. Katona is the Director of the Gastrointestinal Cancer Genetics Program and Risk Evaluation Program and the Lynch Syndrome Program at Penn Medicine...
Jun 20, 20240
Guest: Andres J. Yarur, MD Obesity has recently surfaced as an important topic in patients with inflammatory bowel diseases, such as Crohn’s and ulcerative colitis, but historically, these patients have been underweight. This led to the phase III pivotal trials for the use of upadacitinib in patients with moderate to severe ulcerative colitis and Crohn’s disease to see how their baseline BMI would influence the efficacy of the drug. To hear the details and findings of this study, join Dr. Andres...
Jun 17, 20240
Guest: Andres J. Yarur, MD Health maintenance emphasizes health promotion and disease prevention, which is very important for patients with inflammatory bowel disease (IBD) since they’re at an increased risk of several life-threatening conditions. Tune in to hear Dr. Andres Yarur discuss essential health maintenance strategies for patients with IBD. Dr. Yarur is an Associate Professor of Medicine at Cedars Sinai Medical Center in Los Angeles, California.
Jun 14, 20240
Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Michael Camilleri, MD When it comes to irritable bowel syndrome (IBS), it’s important to keep in mind that there are certain diagnoses clinicians can make to specifically treat the underlying problem that’s causing the symptoms that suggest IBS. To learn more about these complex mimickers, join Dr. Peter Buch as he speaks with Dr. Michael Camilleri, Professor of Medicine at the Mayo Clinic College of Medicine and Science....
Jun 11, 20240
Host: Peter Buch, MD, FACG, AGAF, FACP Guest: David P. Hudesman, MD There’s been an increase in the elderly irritable bowel disease (IBD) population, and it’s estimated that a third of our overall IBD population will soon be over the age of 60. When managing and diagnosing these patients, there’s different factors to consider, like polypharmacy, biological versus chronological age, how fit these patients are versus how frail they are, and more. To take a deep dive into how IBD is affecting elder...
May 16, 20240
Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Francis Farraye, MD Patients with inflammatory bowel disease (IBD) have an increased risk of developing infections, and some may be preventable with a vaccine. Approximately 70 percent of patients with ulcerative colitis or Crohn’s disease will be on immunosuppressive therapy at some point during their treatment course, so it’s best to try to address vaccines before they’re immunosuppressed. So to walk us through some strategies for increasing the nu...
May 01, 20240
